Systemic Therapies for mHSPC and Castrate Resistant Prostate Cancer

New Standards of Care for Advanced Prostate CancerПодробнее

Systemic Therapies for mHSPC and Castrate Resistant Prostate CancerПодробнее

Debate: Prostate Cancer Patients Should/Should Not Get Chemo and ADT as a Standard of CareПодробнее

Systemic Therapies for the Treatment of Advanced Prostate CancerПодробнее

Systemic Therapy for Nonmetastatic Castrate-Resistant Prostate CancerПодробнее

Evolution of Treatment for Metastatic Castration-Resistant Prostate CancerПодробнее

Castration Resistant Prostate Cancer - Developments and Challenges from 2020Подробнее

Examining Metastatic Castration-Resistant Prostate Cancer Treatment in Black PatientsПодробнее

Updates in the treatment of castration-resistant prostate cancerПодробнее

Metastatic Castration Resistant Prostate Cancer (mCRPC) – Inroads in Improved OutcomesПодробнее

A Case of Metastatic Castration-Resistant Prostate CancerПодробнее

Living with Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC): Ron and Laurie’s storyПодробнее

The evolving treatment landscape of mHSPC and mCRPCПодробнее

Exploring The Evolution In Metastatic Hormone Sensitive & Castration Resistant Prostate CancerПодробнее

Enzalutamide + ADT in Men with De Novo mHSPC: The ARCHES TrialПодробнее

Patient Selection in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)Подробнее

Current developments in castration-resistant prostate cancer therapiesПодробнее

Targeting AR in Castration Resistant Prostate CancerПодробнее

PARP inhibitors for the treatment of metastic castration-resistant prostate cancerПодробнее

Sipuleucel-T in Castration-Resistant Prostate CancerПодробнее